Literature DB >> 12559184

Clinical outcomes after laparoscopic antireflux surgery in patients with and without preoperative endoscopic esophagitis.

Ketan M Desai1, Margaret M Frisella1, Nathaniel J Soper2.   

Abstract

A wide spectrum of endoscopic findings exists in patients with gastroesophageal reflux disease (GERD). This study compared clinical outcomes after laparoscopic antireflux surgery (LARS) in patients who had GERD with and without preoperative endoscopic esophagitis. From 1992 to 2001, a total of 414 patients who underwent LARS with 6 months or more of follow-up were prospectively entered into a database. Among these patients, 84 (20%) had no endoscopic evidence of esophagitis on preoperative endoscopy (group 1), whereas 330 (80%) did have esophagitis (group 2). Perioperative outcomes, GERD symptom relief, and the use of acid-reducing medication were assessed. Preoperative DeMeester scores in groups 1 and 2 were 44 +/- 29 and 61 +/- 62 (P < 0.05) and mean esophageal peristaltic amplitude was 86 +/- 32 mm Hg vs. 60 +/- 42 mm Hg, respectively (P < 0.05). Although procedure time was significantly shorter in group 1, other perioperative outcomes were similar. At postoperative follow-up, the use of proton pump inhibitors was reduced in both groups (86% to < or =14%). With the exception of postoperative dysphagia, there was no difference in GERD symptom relief between groups 1 and 2. The presence or absence of preoperative esophagitis has minimal effect on favorable symptomatic outcomes after LARS. Thus LARS is an effective treatment option for patients, irrespective of endoscopic evidence of esophagitis, leading to excellent symptom relief and a marked reduction in the use of proton pump inhibitors. Copyright 2003 The Society for Surgery of the Alimentary Tract, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12559184     DOI: 10.1016/S1091-255X(02)00135-X

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  25 in total

1.  Circadian esophageal motor function in patients with gastroesophageal reflux disease.

Authors:  H J Stein; E P Eypasch; T R DeMeester; T C Smyrk; S E Attwood
Journal:  Surgery       Date:  1990-10       Impact factor: 3.982

2.  Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux--the "sensitive oesophagus".

Authors:  R G Watson; T C Tham; B T Johnston; N I McDougall
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

3.  Effects of antireflux procedures on respiratory symptoms.

Authors:  Kevin L Greason; Daniel L Miller; Claude Deschamps; Mark S Allen; Francis C Nichols; Victor F Trastek; Peter C Pairolero
Journal:  Ann Thorac Surg       Date:  2002-02       Impact factor: 4.330

4.  Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.

Authors:  J P Galmiche; P Barthelemy; B Hamelin
Journal:  Aliment Pharmacol Ther       Date:  1997-08       Impact factor: 8.171

5.  Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis.

Authors:  C M Bate; J R Green; A T Axon; F E Murray; G Tildesley; C E Emmas; M D Taylor
Journal:  Aliment Pharmacol Ther       Date:  1997-08       Impact factor: 8.171

6.  Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice.

Authors:  T L Venables; R D Newland; A C Patel; J Hole; M B Copeman; M L Turbitt
Journal:  Scand J Gastroenterol       Date:  1997-07       Impact factor: 2.423

7.  Heartburn--the acid test.

Authors:  B Joelsson; F Johnsson
Journal:  Gut       Date:  1989-11       Impact factor: 23.059

Review 8.  Endoscopy-negative gastroesophageal reflux disease. The hypersensitive esophagus.

Authors:  S R Achem
Journal:  Gastroenterol Clin North Am       Date:  1999-12       Impact factor: 3.806

9.  A physiologic approach to laparoscopic fundoplication for gastroesophageal reflux disease.

Authors:  J G Hunter; T L Trus; G D Branum; J P Waring; W C Wood
Journal:  Ann Surg       Date:  1996-06       Impact factor: 12.969

10.  Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.

Authors:  T L Venables; R D Newland; A C Patel; J Hole; C Wilcock; M L Turbitt
Journal:  Scand J Gastroenterol       Date:  1997-10       Impact factor: 2.423

View more
  10 in total

Review 1.  Guidelines for surgical treatment of gastroesophageal reflux disease.

Authors:  Dimitrios Stefanidis; William W Hope; Geoffrey P Kohn; Patrick R Reardon; William S Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2010-08-20       Impact factor: 4.584

2.  Laparoscopic cardial calibration and gastropexy for treatment of patients with reflux esophagitis: pathophysiological basis and result.

Authors:  Italo Braghetto; Owen Korn; Anibal Debandi; Patricio Burdiles; Hector Valladares; Attila Csendes
Journal:  World J Surg       Date:  2005-05       Impact factor: 3.352

3.  Laparoscopic fundoplication: a 10-year learning curve.

Authors:  D Zacharoulis; C J O'Boyle; P C Sedman; W A Brough; C M S Royston
Journal:  Surg Endosc       Date:  2006-10-05       Impact factor: 4.584

4.  Laparoscopic Nissen fundoplication in patients with nonerosive reflux disease. Long-term quality-of-life assessment and surgical outcome.

Authors:  T Kamolz; F A Granderath; U M Schweiger; R Pointner
Journal:  Surg Endosc       Date:  2005-02-03       Impact factor: 4.584

5.  [Nonerosive and erosive gastroesophageal reflux disease. Long-term results of laparoscopic anterior semifundoplication].

Authors:  I Gockel; A Heintz; M Domeyer; W Kneist; T T Trinh; T Junginger
Journal:  Chirurg       Date:  2007-01       Impact factor: 0.955

6.  Radiologic and endoscopic characteristics of laparoscopic antireflux wrap: correlation with outcome.

Authors:  Italo Braghetto; Owen Korn; Attila Csendes; Héctor Valladares; Cristóbal Davanzo; Aníbal Debandi
Journal:  Int Surg       Date:  2012 Jul-Sep

7.  The use of medication after laparoscopic antireflux surgery.

Authors:  Ruxandra Ciovica; Otto Riedl; Christoph Neumayer; Wolfgang Lechner; Gerhard P Schwab; Michael Gadenstätter
Journal:  Surg Endosc       Date:  2009-01-24       Impact factor: 4.584

8.  LAPAROSCOPIC REDO FUNDOPLICATION ALONE, REDO NISSEN FUNDOPLICATION, OR TOUPET FUNDOPLICATION COMBINED WITH ROUX-EN-Y DISTAL GASTRECTOMY FOR TREATMENT OF FAILED NISSEN FUNDOPLICATION.

Authors:  Italo Braghetto; Owen Korn; Manuel Figueroa-Giralt; Catalina Valenzuela; Ana Maria Burgos; Carlos Mandiola; Camila Sotomayor; Eduardo Villa
Journal:  Arq Bras Cir Dig       Date:  2022-09-09

Review 9.  Pre-operative clinical and instrumental factors as antireflux surgery outcome predictors.

Authors:  Salvatore Tolone; Giorgia Gualtieri; Edoardo Savarino; Marzio Frazzoni; Nicola de Bortoli; Manuele Furnari; Giuseppina Casalino; Simona Parisi; Vincenzo Savarino; Ludovico Docimo
Journal:  World J Gastrointest Surg       Date:  2016-11-27

10.  Antireflux surgery is equally beneficial in nonerosive and erosive gastroesophageal reflux disease.

Authors:  Joong-Min Park; Kyong-Choun Chi
Journal:  Ann Surg Treat Res       Date:  2017-07-30       Impact factor: 1.859

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.